Physician profile
Steven E Day
NPI 1528066594
$2,217.33
in general payments reported to CMS, 2019-2025
9 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $330 · 2021: $291 · 2022: $463 · 2023: $277 · 2024: $214 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.63 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $666.71 | 2019-2022 | |
| Abbvie INC. | $615.29 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan, Vuity |
| Alcon Vision LLC | $345.52 | 2022-2025 | Rocklatan, Rhopressa, Simbrinza |
| Ivantis, INC | $163.12 | 2020 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $115.37 | 2019-2020 | |
| Allergan, INC. | $102.61 | 2019-2020 | |
| Glaukos Corporation | $54.59 | 2021 | |
| Sun Pharmaceutical Industries INC. | $29.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,669.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.